Company Overview of Elusys Therapeutics, Inc.
Elusys Therapeutics, Inc. operates as a biopharmaceutical company that develops antibody therapeutics for the treatment of life-threatening infectious disease. The company develops Anthim, a humanized and deimmunized monoclonal antibody that targets the protective antigen of B. anthracis and neutralizes the lethal effects of anthrax toxins. Elusys Therapeutics, Inc. was formerly known as ErythroMed, Inc. The company was founded in 1998 and is based in Pine Brook, New Jersey.
25 Riverside Drive
Pine Brook, NJ 07058
Founded in 1998
Key Executives for Elusys Therapeutics, Inc.
Senior Director of Human Resources & Administration
Vice President of Corporate Development
Vice President of Development and Manufacturing
Compensation as of Fiscal Year 2014.
Elusys Therapeutics, Inc. Key Developments
Elysys Therapeutics, Inc. Presents at BioNJ CEO Summit 2013, Oct-04-2013 08:00 AM
Oct 4 13
Elysys Therapeutics, Inc. Presents at BioNJ CEO Summit 2013, Oct-04-2013 08:00 AM. Venue: Bridgewater Marriott, Bridgewater, New Jersey, United States. Speakers: Elizabeth Posillico, President and CEO.
Elusys Therapeutics, Inc. Presents at 12th Annual BIO Investor Forum, Oct-08-2013 09:30 AM
Aug 9 13
Elusys Therapeutics, Inc. Presents at 12th Annual BIO Investor Forum, Oct-08-2013 09:30 AM. Venue: The Palace Hotel, 2 New Montgomery Street, San Francisco, CA 94105, United States.
Elusys Wins Additional $14.5 Million Under Existing U.S. Government Contracts Supporting Expanded Human Safety Studies of ETI-204 for Treatment of Inhalational Anthrax
Sep 13 12
Elusys Therapeutics, Inc. announced that it has been awarded additional funding from the U.S. Government, valued at $14.5 million, to support expanded human safety studies of ETI-204 (Anthim), an investigational agent for the treatment of anthrax infection following a biowarfare attack. The company has now received $149 million, under two advanced development contracts with a potential total value of $211 million, from the Biomedical Advanced Research and Development Authority, within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services. ETI-204 is an investigational anti-toxin and is a promising candidate for the treatment of inhalational anthrax in humans. The $14.5 million funding will be used to conduct final, expanded safety studies for intravenous (IV) administration of ETI-204, as well as a dose escalation safety study for intramuscular (IM) administration of the anti-toxin. IM administration would allow rapid administration of anti-toxin treatment to large numbers of people in an emergency setting. Elusys has also received funding previously from the U.S. Department of Defense to support the development of its IM formulation.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|